World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Research Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2025
Volume: 4; Issue: 4
Page: 502-514

ANTIBODY-DRUG CONJUGATES AND BISPECIFIC ANTIBODIES: THE NEW CORNERSTONES OF TARGETED CANCER THERAPY

Ancelin Wilfy[1*] and Mukesh M.[2]

[1]Pharm.D, JSS College of Pharmacy, Ooty.
[2]M.Pharm, Adhiparasakthi College of Pharmacy.

Article Received: 04 July 2025 | | Article Revised: 25 July 2025 | | Article Accepted: 18 August 2025

***Corresponding Author: Ancelin Wilfy**
Pharm.D, JSS College Of Pharmacy, Ooty.
DOI: https://doi.org/10.5281/zenodo.16932346

How to cite this Article: Ancelin Wilfy, Mukesh M (2025) ANTIBODY DRUG CONJUGATES AND BISPECIFIC ANTIBODIES: THE NEW CORNERSTONES OF TARGETED CANCER THERAPY. World Journal of Pharmaceutical Science and Research, 4(4), 502-514. https://doi.org/10.5281/zenodo.16932346

ABSTRACT

ADCs and BsAbs herald a new era for targeted cancer therapies with enhanced specificity, less systemic toxicity, and better clinical outcomes. ADCs are conjugates comprising monoclonal antibodies and potent cytotoxic drugs. They provide in vitro tumor cell death mediated by binding and cellular uptake of monoclonal antibody into the undesirable cells. BsAbs in contrast bind tumor-associated antigens at one end and immune effector cells at the other, essentially redirecting the immune system to kill tumor cells. Both modalities, however, present clinical advantages for the treatment of hematologic and solid malignancies with many of the variants already having gained regulatory approval, while many others are still at different stages of clinical development. Certainly, resistance, restricted antigen expression, and toxicities caused by cytokines are some of the challenges faced. However, recent advances in antibody engineering, linker, and payload design have rapidly eliminated these pitfalls. This review focuses on the structure, mechanism, clinical applications, current approvals, and potential advances to date in the field of ADCs and BsAbs that are set to transform cancer therapeutics for future precision medicine.

KEYWORDS: Antibody-Drug Conjugates (ADCs), Bispecific Antibodies (BsAbs), Targeted Cancer Therapy, Monoclonal Antibodies, Immunotherapy, Tumor Antigen.

INTRODUCTION

Cancer therapy has witnessed all sorts of transformations over the last few decades before. Classical methods such as surgery, radiation, and cytotoxic chemotherapy were used to lessen tumor burden but were indiscriminate in nature and result in severe adverse reactions in healthy tissues. The fact that these chemotherapeutic agents act in a non-selective

manner means that their systemic effect is highly toxic. The conceptualization of cancer on a molecular level and development of targeted therapies thus marked a paradigm shift in cancer therapy. This process was largely propelled by the developments in molecular biology, genomics, and immunology, which hastened the development of therapies designed to interfere with particular molecular targets that are essential for tumor growth and survival. From hormone therapies for breast and prostate cancers to tyrosine kinase inhibitors and monoclonal antibodies, cancer treatment has indeed taken a very mechanistic turn toward a more personalized direction.[1]

The new approach brought targeted therapies a new precision level in oncology medicine, emphasizing certain molecular pathways behind cancer progression. While chemotherapy acts in a general manner affecting all cells, targeted therapy drugs are supposed to home in on, bind, and block a protein or receptor present on the cancer. Hence, the targeted therapy minimizes damage to normal cells. Below, we have some examples of these therapies: monoclonal antibodies, small molecule inhibitors, and immunotherapy, including checkpoint inhibitors. Nonetheless, many of them, despite their fame, have had to endure resistance mechanisms being posed against them, ineffectiveness in tumor penetration, or side effects created by targeting cells other than cancerous ones. These limitations have required the evolution of more advanced biologic agents such as the ADCs and BsAbs to further improve efficacy and selectivity.[2] One of the major limitations of both conventional chemotherapeutic and newly discovered agents is the lack of absolute tumor specificity, and consequently, toxicity and dosing are restricted. Similarly, since cancer cells share many features with normal cells, selective targeters that will not affect healthy tissue pose a huge challenge. Additionally, the tumor heterogeneity and antigen escape mechanisms can diminish single target therapies. In that context, novel strategies that truly couple high specificity with maximum cytotoxic effect are necessary; ADCs and BsAbs were the suggested answers. These therapies therefore constitute a better and safer cancer treatment compared to classic treatments in that they combine monoclonal antibodies' ability to target antigens with the delivery of cytotoxic drugs or redirection of immune cells.[3]

Antibody-Drug Conjugates (ADCs) appear as engineered molecules consisting of a monoclonal antibody and a cytotoxic drug (payload) joined together by a chemical linker, such that chemotherapy is delivered too directly into the tumor cells, limiting systemic exposure. Meanwhile, Bispecific Antibodies (BsAbs) are designed to simultaneously bind two different antigens-an antigen associated with a tumor and the other, a marker of immune cells like CD3-for immune cell activation and direct tumor killing. With both ADCs and BsAbs combining molecular targeting with extra anti-tumor mechanisms, they thus represent forefront modalities in oncology. The growing success in hematologic and solid tumors and the approvals they have recently obtained highlight their arraying as the new key tools of present-day cancer therapy.[4]

TARGETED CANCER THERAPY

A targeted therapeutic on a molecular level will interfere with tumor growth, progression, and survival. In contrast to chemotherapy, able to kill fast-growing normal cells, targeted treatments attack cancer cells due to peculiar molecular features. Such therapeutics are based on sophisticated knowledge of cancer biology, including agents like monoclonal antibodies, tyrosine kinase inhibitors, and, most recently, scene actors such as antibody-drug conjugates (ADCs) and bispecific antibodies (BsAbs). One of the major principles is specificity, avoiding off-target effects, and interacting with critical signaling pathways, tumor-associated antigens, or the tumor microenvironment. By exploiting molecular differences between cancerous and normal tissues, targeted therapies seek to boost therapeutic efficacy and reduce adverse toxicity.[5]

Conventional chemotherapy remains an important arm of many anticancer regimens but has some inherent problems, mainly its non-specificity. These agents injure both cancerous and normal rapidly dividing cells, causing side effects like myelosuppression, mucositis, alopecia, and gastrointestinal toxicity. Besides this, chemotherapy also causes multidrug resistance such as a multi-drug efflux pump or the increased repair of drugs on DNA. Monoclonal antibodies (mAbs) have enhanced tumor targeting to some degree. Nonetheless, even the best have an Achilles heel below some tumor antigen density or are thwarted by internalization inefficiency or immune evasion mechanisms. As a consequence, they are often partnered with cytotoxic drugs to create a larger and meaningful tumor regression. They highlight the need for a class of biologics that could potentially combine greater potency with higher precision, leading to the advent of ADCs and BsAbs.[6]

ANTIBODY-DRUG CONJUGATES (ADCS)

Antibody-Drug Conjugates (ADCs) are engineered therapeutics combining the selectivity of monoclonal antibodies with the potency of cytotoxic drugs. The core concept behind ADCs is targeting a toxic payload specifically to malignant cells with minimal exposure to normal tissues. Each ADC comprises three fundamental components: the antibody, the linker, and the toxic payload. The design and interplay between these three components govern an ADC's efficacy, safety, and pharmacokinetics.[7]

Structure and Components

1. Monoclonal Antibody

The antibody is made so as to bind to a certain protein (antigen) found mainly on the cancer cells. After binding, the ADC is usually internalized inside the cell by internalization. This step aids in drug delivery to the exact spot where it is needed within the cancer cell.

2. Linker

The linker essentially acts as a chemical connector that joins the drug (payload) to the antibody. It must keep the drug securely attached while the ADC is cruising through the bloodstream and then release it once inside the cancer cell. Such linkers come into two varieties:

- **Cleavable linkers**: They basically break down inside the cancer cell so the drug gets released.
- **Non-cleavable linkers**: They stay attached until the whole ADC is degraded inside the cell.

3. Cytotoxic Payload

The payload is the actual drug that kills cancer cells, such as cytotoxic agents. They are usually 100 to 1000 times more potent than standard chemotherapy drugs-warranting very precise delivery. The main types are:

- **Microtubule inhibitors**: These stop cells from dividing into two daughter cells (e.g., MMAE, DM1).
- **DNA-damaging agents**: They break or damage the DNA of cells
- **Topoisomerase I inhibitors**: They interfere with the process of DNA replication.[8,9]

MECHANISM OF ACTION OF ANTIBODY-DRUG CONJUGATES (ADCS)

1. Target Recognition and Binding

To kill the cancer cell, one must actually locate the cell by recognizing it, for the mechanism of action of ADCs depends on this step. Each ADC carries a monoclonal antibody that is engineered to recognize and bind to an antigen that is highly expressed on the surface of cancer cells but least expressed on healthy cells. Such heightened specificity

targets the ADC to tumor cells, thereby preventing collateral damage to normal tissue. The target chosen is subject to some criteria: it must be present in ample numbers on tumor cells, accessible from the extracellular space to an antibody, and when bound, capable of initiating internalization into the cell.[10]

2. Internalization into the Cancer Cell

After the antibody part of the ADC binds to the target antigen on the surface of the cancer cell, the ADC-antigen complex is then endocytosed into the cell through receptor-mediated endocytosis. The ADC is engulfed in a membrane-bound vesicle termed an endosome. This internalization step is an absolute necessity for the cytotoxic drugs of ADCs to exert their activities inside the target cell. Without the internalization, the drug payload cannot be released in the compartment where it is needed.[11]

3. Trafficking to Lysosomes and Payload Release

Upon entering the cell, the endosome bearing the ADC merges with a lysosome with an enzymatic and acidic environment. The lysosomal environment is conducive to the breakdown of the linker between the antibody and the drug. Depending on the type of linker, these mechanisms could facilitate drug release: cleavable linkers release drugs when they are cleaved either enzymatically or by changes in pH, whereas non-cleavable linkers require complete lysosomal degradation of the antibody to release the payload.[12]

4. Cytotoxic Action and Cell Death

After being released into the cytosol of the cancer cell, they exert their cytotoxic effects. Generally, such payloads are exceedingly potent, designed to disrupt vital cellular processes. They might inhibit microtubule functions to stop cell division causing apoptosis or otherwise damage the DNAs by causing double strand breaks so it cannot replicate (e.g., calicheamicin, duocarmycin). Owing to lethality, targeted delivery helps maintain the undesired effects foremost in cancer cells, thus minimizing systemic toxicity.[13]

5. Bystander Killing Effect (Optional in Some ADCs)

These released drugs may diffuse out of the target cancer cell and kill adjacent tumor cells that perhaps do not express the target antigen in certain ADCs, particularly those with cleavable linkers and membrane-permeable payloads. This is called the bystander killing effect. This phenomenon becomes especially beneficial in tumors exhibiting heterogeneous antigen expression, wherein not all cancer cells express the target marker. It allows the killing of cells only adjacent to the ones conventionally targeted by the ADC.[14]

EVOLUTION AND GENERATIONS OF ANTIBODY-DRUG CONJUGATES (ADCS)

Generation	Key Features	Examples
First Generation	- Early ADCs with basic antibodies - Unstable linkers - Less potent drugs	Gemtuzumab ozogamicin (initial version)
Second Generation	- Improved humanized antibodies - More stable cleavable/non-cleavable linkers - Highly potent payloads like MMAE, DM1	Trastuzumab emtansine (T-DM1), Brentuximab vedotin
Third Generation	- Site-specific conjugation - Better control of Drug-Antibody Ratio (DAR) - New payloads (e.g., topoisomerase inhibitors) - Effective in solid tumors- Bystander killing effect	Trastuzumab deruxtecan (T-DXd), Sacituzumab govitecan
Future Generations	- Dual-payload ADCs- Tumor-activated ADCs - Immune-stimulating payloads - Combination with immunotherapy	Under development[15]

RESISTANCE MECHANISMS TO ADCS

1. Antigen Downregulation or Loss

For ADCs to work, they have to bind to a certain antigen on a cancer cell. When cancer cells reduce the expression of the antigen, or perhaps lose it completely, the ADCs cannot bind and enter into these cells; hence, the treatment fails. An example is HER2 loss in breast cancer that leads to resistance toward HER2-targeting ADCs like T-DM1.

2. Impaired Internalization

Upon binding to the cancer cell surface, the ADC needs to be internalized and undergo intracellular trafficking so that the drug is released. Certain resistant cells impair or at least reduce the rate of internalization, thus preventing the ADC from reaching the lysosomes to release the toxic drug.[16]

3. Defective Lysosomal Function

Once internalized, the ADC goes to the lysosome, where the drug is meant to be released, but if the lysosomes do not work properly-for example, having coloration of the pH or enzyme levels-the payload may not be released well, lessening the killing ability of the ADC.

4. Efflux Pump Overexpression

Some cancer cells increase the activity of efflux pumps (e.g., P-glycoprotein) that pumps the drug back outside the cell before it can act. It is a usual mechanism of resistance common with the anticancer therapy and limits antimicrotubular drugs-like MMAE acting cancer ADCs.[17]

5. Drug Payload Modification or Detoxification

Cancer cells may develop a means of inactivating or degrading the payload (the toxic drug) before it can exert any damage. Methods of modification of the released drug, or enhanced expressions of enzymes that detoxify it, will directly reduce the potency of the drug released inside' the cell.

6. Tumor Heterogeneity

Not all cancer cells in a tumor are the same. Some may express the target antigen, while others don’t. That heterogeneity may contribute to only some cancers being killed by a treatment; hence the resistant ones grow and spread.[18]

CLINICAL APPLICATIONS OF ANTIBODY-DRUG CONJUGATES (ADCS)

1. Hematologic Malignancies

ADCs have made a major impact on hematologic cancers. A case in point is Brentuximab vedotin, an ADC targeting CD30, which has been approved for classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma with an outstanding impact on outcomes in the relapsed or refractory setting. Inotuzumab ozogamicin, targeting CD22, acts in relapsed or refractory B-ALL. Inotuzumab ozogamicin showed high rates of complete remission and was most beneficial in MRD-positive cases; it provides a bridge to stem cell transplantation.

2. Breast Cancer

HER2-positive breast cancer has been highly developed for ADC preparation. Trastuzumab emtansine (T-DM1), an ADC combining trastuzumab with the cytotoxic drug DM1, is given to patients who progress after therapy with trastuzumab and some form of chemotherapy. Trastuzumab deruxtecan (T-DXd), a second-generation HER2-targeted

ADC, has showcased greater efficacy and has been approved for use even in less advanced lines of treatment. T-DXd's high drug-to-antibody ratio coupled with its bystander killing effect enables it to target tumors with heterogeneous HER2 expression.[19]

3. Urothelial Cancer

Enfortumab vedotin, targeting Nectin-4, is approved for patients with advanced urothelial carcinoma who have previously received both chemotherapy and immune checkpoint inhibitors. It delivers a potent cytotoxic agent directly to tumor cells, offering a meaningful survival benefit and response in a patient population with limited treatment options.

4. Lung Cancer

While trastuzumab deruxtecan (T-DXd) is heralded as a therapy of hope for the small subgroup of non-small cell lung cancer (NSCLC) harboring HER2 mutations that lack effective targeted options, it is an ADC that gave high ORR and durable benefits in clinical trials, thereby earning its approval-the move being an important example of how lung cancer with HER2 alterations has entered the domain of precise therapy.[20]

5. Ovarian and Gastric Cancers

In platinum-resistant ovarian cancer, mirvetuximab soravtansine targeting folate receptor alpha is being trialed and has shown promise in clinical trials. For HER2-positive gastric cancer, trastuzumab deruxtecan (T-DXd) has equally shown efficacy and is an important therapeutic alternative in regions where expression of HER2 is more common in gastric tumors.

6. Ongoing Clinical Trials and Future Applications

There are several ADCs currently in clinical development for pancreatic, colorectal, prostate, and glioblastoma tumors, in addition to well-established indications. They may target new antigens such as Trop-2, PTK7, and PSMA to extend indications for ADCs. As innovation continues with new payloads, linkers, and antibody designs, therapeutic changes are expected to unfold rapidly so as to further extend the clinical applications of ADCs.[21]

SAFETY PROFILE

ADCs provide inherent targeted therapy for cancer but also bring a plethora of adverse events that need to be looked upon in detail and managed accordingly. The most common toxicities include hematologic effects such as neutropenia and thrombocytopenia, which are often associated with the payload and thus are managed by dose modifications and supportive care. Hepatotoxicity is seen with some agents such as trastuzumab emtansine, so it is important to monitor liver function regularly. Peripheral neuropathy may be evident with agents such as microtubule inhibitors (e.g., MMAE), and can go on treatment delays or drug discontinuation. Ocular toxicities including blurred vision and keratitis could be prevented with prophylactic eye drops and regular eye exams. Infusion-associated reactions like fever or hypotension are generally being treated with premedication and slowing the infusion rate. Another side effect is gastrointestinal upset, such as nausea and vomiting, treated with antiemetics and hydration. In general, early recognition and supportive care should be given to minimize patient discomfort and treatment-related interruptions, thereby optimizing therapy.[22]

BISPECIFIC ANTIBODIES (BSABS): DUAL TARGETING INNOVATION

Bispecific antibodies (BsAbs) constitute an interesting space in cancer immunotherapy. They are engineered to simultaneously recognize two different antigens or epitopes. Unlike monoclonal antibodies that only recognize one target, BsAbs can bind a tumor antigen and an effector cell of the immune system, which is mostly T cells, to direct the destruction of tumor cells.

These molecules have been engineered into different formats, including IgG-like molecules containing an Fc region for better stability and half-life and smaller Fc-free formats such as BiTEs, which provide better tissue penetration and the ability of quick action. All these formats are designed either to bring the T cells in close contact with tumor cells (e.g., CD3 × tumor antigen), inhibit two signaling pathways (e.g., HER2 × HER3), or block dual immune checkpoints (e.g., PD-1 × CTLA-4). This maximizes the therapeutic potential.[23]

Clinically, BsAbs have exhibited remarkable efficacy in hematologic malignancies. A case in point is blinatumomab treatment for acute lymphoblastic leukemia that has completely revolutionized the therapy options available for it. Rapid developments are underway into the application of BsAbs in solid tumors, with newer constructs being more tumor selective, less likely to generate off-target side effects, and are overcoming resistance mechanisms seen with single-agent therapies.

By crosslinking immune effector functions with precise targeting, BsAbs constitute a potent weapon in the oncologist's armamentarium that provides an impetus for curing cancers resistant to conventional treatment. The scope of precision cancer immunotherapy is now being reshaped with their novel dual-targeting mechanism.[24]

Structure and Classification of Bispecific Antibodies (BsAbs)

Bispecific antibodies (BsAbs) represent a category of engineered antibodies that simultaneously have affinity for two different target molecules. Their structure is designed such that each "arm" of the antibody recognizes a separate antigen. This peculiar double-binding property thus permits BsAbs to physically link immune effector cells (T cells or NK cells) to cancer cells for more precise immune attack on tumor cells.

Structure

- **Two binding sites:** One site binds to a cancer cell (e.g., HER2, CD20), and the other binds to an immune cell (e.g., CD3 on T cells).
- **With or without Fc region:** If one includes the Fc (fragment crystallizable) region like normal antibodies, they will have a longer half-life. Otherwise, without Fc regions, it is shorter and smaller in size for better tissue penetration.[25]

Classification

Category	Type	Features	Example
Structural Classification	IgG-like BsAbs	Full antibody structure, includes Fc region, longer half-life	Knobs-into-holes, CrossMab
	Non-IgG-like BsAbs	Lacks Fc region, smaller size, shorter half-life, fast action	BiTEs (e.g., Blinatumomab)
Functional Classification	Immune Cell Redirecting	Binds tumor antigen and immune cell (e.g., CD3) to promote killing	CD3 × CD19 (Blinatumomab)
	Dual Immune Checkpoint Blockers	Blocks two immune checkpoints to enhance immune response	PD-1 × CTLA-4 BsAb

	Dual Tumor Antigen Targeting	Targets two tumor antigens to prevent escape and increase specificity	HER2 × HER3 BsAb[26]

MECHANISM OF ACTION OF BISPECIFIC ANTIBODIES (BSABS)

1. Immune Cell Redirection (T-cell Engagers and NK-cell Engagers)

The major function of various BsAbs, including BiTEs (Bispecific T-cell Engagers), is to recruit cytotoxic immune cells to tumor cell sites. BsAbs bind an antigen present on the tumor cell surface (e.g., CD19, HER2) via one binding site and an immune cell receptor (e.g., CD3 on T cells or CD16 on NK cells) at the other. Thus, the immune effector cell is brought into close contact with the target cancer cell by the BsAb. This interaction triggers immune synapse formation, activates the T cells, and kills the tumor cells in a manner involving perforins, granzymes, and inflammatory cytokines like IFN-γ and TNF-α-all independent of the MHC recognition system.[27]

2. Dual Tumor Antigen Targeting

Another approach used by some BsAbs is to target two antigens that may be present on the tumor cell surface. This mechanism helps to increase tumor specificity and prevents antigen escape away-a common resistance mechanism in monoclonal antibody therapies. For example, HER2 × HER3 BsAbs will block heterodimer formation that drives tumor proliferation but will also increase receptor internalization and degradation to downregulate signaling cascades.[28]

3. Dual Pathway Blockade

Where many signaling cascades function, BsAbs can implicate a complete blockade of redundant or compensatory mechanisms. BsAbs, which inhibit two oncogenic pathways simultaneously (e.g., EGFR and MET), do not allow tumor cells to circumvent the targeted therapy and thus lead to an increase of the therapeutic effects and delayed resistance.[29]

4. Dual Immune Checkpoint Inhibition

Certain BsAbs act to inhibit two immune checkpoint proteins (such as PD-1 and CTLA-4) in order to lift tumor-induced immunosuppression and revive anti-tumor immunity. Such a double inhibition can lead to a stronger and longer-lasting T-cell response than monotherapy checkpoint inhibitors.[30]

5. Crosslinking and Receptor Internalization

Bispecific antibodies can crosslink receptors, driving their internalization and degradation, and thereby reducing the expression of critical growth receptors on tumor cells. Internalization also opens up a pathway for payload delivery in ADC-like bispecific antibody formats, combining dual targeting with direct cytotoxic delivery.[31]

CHALLENGES WITH BISPECIFIC ANTIBODIES (BSABS)

1. Cytokine Release Syndrome (CRS)

Cytokine Release Syndrome (CRS) is one of the most common immune-related adverse effects of BsAbs, especially the T-cell engaging ones. Secondary to rapid immune activation and cytokine release, the syndrome's symptoms include fever, hypotension, and organ dysfunction. Treatment includes step-up dosing and anti-inflammatory agents such as corticosteroids and tocilizumab, which help in mitigating the symptoms and ensuring that treatment may continue.

2. Neurotoxicity

Neurotoxicity poses another major concern, particularly alongside CD3-targeting BsAbs. Patients could develop alterations in consciousness, seizures, or impairment of language. It is thought to be immune-mediated and unpredictable. There should be close neurological monitoring, dose interruptions when indicated, and supportive care in order to minimize risk and support the safety of the patient while on therapy.[32]

3. Short Half-Life and Complex Dosing

Early-generation drugs like blinatumomab have extremely short half-lives that require continual IV infusion, which complicates the logistics of treatment and limits its use in the outpatient setting and convenience. Some new approaches are to foster Fc-fusion BsAbs and subcutaneous formulations with long half-life for ease of administration less frequently.

4. Tumor Antigen Escape

Some tumors evade BsAb therapies by downregulation or loss of target antigen expression, called antigen escape, leading to relapse or resistance. Strategies to prevent the development of antigen escape include dual-targeting BsAbs, combination therapies, and selecting more stable or multiple tumor-associated antigens.

5. Manufacturing Complexity

Manufacturing BsAbs is a difficult task because of the types of dual bindings present. It has to be ensured that no mispairing of heavy and light chains occurs into the desired arrangement. These engineering technologies, for example, CrossMab and knobs-into-holes, however, pose further hurdles and cost restrictions to large-scale manufacture and hence restrict access.[33]

CLINICAL APPLICATIONS OF BISPECIFIC ANTIBODIES (BSABS)

1. Hematologic Malignancies

The fastest to gain regulatory approval and most commercially successful clinical application for BsAbs comprises hematologic malignancies, especially of B cells. Blinatumomab, a CD3xCD19 bispecific T-cell engager (BiTE), has been approved for acute lymphoblastic leukemia (ALL) and is under investigation for non-Hodgkin lymphoma (NHL). BsAbs redirect T cells toward malignant B cells and thereby increased cytotoxic activity against them and induce remission in relapsed or refractory cases.

2. Multiple Myeloma

BsAbs targeting BCMA and CD3 are revolutionizing treatment modalities for multiple myeloma. Agents such as teclistamab and elranatamab recruit CD3-positive T cells to interact with BCMA-expressing myeloma cells with resultant potent antitumor activity. This is especially important for heavily pre-treated patients who have undergone all standard therapeutic options. Several BCMA BsAbs have demonstrated deep and sustainable responses in clinical trials.[34]

3. Non-Small Cell Lung Cancer (NSCLC)

Amivantamab had gained approval for NSCLC with an EGFR exon 20 insertion mutation. It blocks two pathways responsible for tumor growth and resistance and hence, acts best in patients who don't respond to the classical EGFR inhibitors. This launches a new era for BsAbs in solid tumors when tumors rely on multiple oncogenic pathways.

4. Colorectal and Gastrointestinal Cancers

In gastrointestinal cancers, including colorectal cancer, BsAbs are being targeted at tumor antigens like CEA (carcinoembryonic antigen) together with CD3 or immune checkpoints. The intention behind these BsAbs is to foster T-cell activation in the tumor microenvironment, possibly circumventing immune resistance and thus raising the response rate for immunotherapy in tumors that are classically non-immunogenic.[35]

5. Prostate and Other Hormone-Driven Cancers

Bispecific antibodies targeting PSMA (prostate-specific membrane antigen) and CD3 are under clinical investigation in prostate cancer. Early results point toward promising antitumor activity, especially in metastatic castration-resistant prostate cancer. The activity of BsAbs may present a targeted immunotherapeutic choice in disease sites where hormonal therapy and chemotherapy have limited effects.

6. Combination with Immune Checkpoint Inhibitors

BsAbs are being employed concurrently with PD-1/PD-L1 inhibitors to circumvent tumor resistance and stimulate immune activation. For example, BsAbs can mediate the colocalization of T cells with tumor cells, whereas checkpoint inhibitors suppress this immune sleep, rendering a synergistic anticancer effect. It is an approach that is being tested in both hematologic and solid tumors.

7. Personalized and Precision Oncology Approaches

On an increasingly frequent basis, BsAbs are being developed based on patient-specific tumor markers to render more personalized treatment. Genomic profiling and biomarker identification enable patient matching with bispecific therapies targeting their own tumor antigens. Such precision enhances therapeutic effect and reduces off-target effects.[36]

DIFFERENCES BETWEEN ANTIBODY-DRUG CONJUGATES (ADCS) AND BISPECIFIC ANTIBODIES (BSABS)

Feature	Antibody-Drug Conjugates (ADCs)	Bispecific Antibodies (BsAbs)
Structure	Monoclonal antibody + cytotoxic drug via a linker	Engineered antibody with two different binding sites
Target	Single tumor antigen	Two targets: often one tumor antigen and one immune cell (e.g., T-cell)
Mechanism of Action	Delivers cytotoxic drug directly into cancer cells	Brings immune cells (e.g., T-cells) into close contact with cancer cells
Cytotoxicity	Drug-induced cell death	Immune-mediated killing (e.g., T-cell activation)
Examples	Trastuzumab emtansine, Brentuximab vedotin	Blinatumomab, Teclistamab
Clinical Use	Common in solid tumors and hematologic cancers	Primarily used in hematologic malignancies; expanding to solid tumors
Side Effects	Neutropenia, fatigue, liver toxicity	Cytokine release syndrome (CRS), neurotoxicity
Resistance Mechanism	Efflux pumps, antigen loss, linker instability	T-cell exhaustion, target antigen loss
Development Focus	Improving linker stability, payload potency[37]	Enhancing immune engagement, reducing CRS[38]

FUTURE DIRECTIONS AND PERSPECTIVES

The field of antibody-drug conjugates (ADCs) and bispecific antibodies (BsAbs) is ever-fast evolving, giving promising avenues for a more tailored and effective approach to treating cancer. Future directions for this field seek to focus on antibody engineering, the development of better linker and payload technologies in ADCs, and engagement of

immune cells in BsAbs for overcoming resistance to and toxicity by these agents. Condition-wise active or tumor microenvironment-responsive ADCs and BsAbs would probably further widen the therapeutic windows by lowering their off-target effects. Integration with other modalities such as the immune checkpoint inhibitors, CAR-T, and nanomedicine would in turn create powerful synergy. Also exciting is the prospect of extending BsAbs applications in solid tumors while designing tri-specific antibodies. The path to truly precision-guided oncology is now open with improvements in biomarker discovery and companion diagnostics, allowing the identification of patients most likely to benefit from these therapies. More clinical trials and regulatory efforts will bring these innovations into mainstream clinical practice.[39,40]

CONCLUSION

The domain of cancer therapy has witnessed a truly revolutionary impact through the venues opened by ADCs and BsAbs. Precisely targeted agents with specified site-toxicity profiles and altogether different coagulation pathways from those of disease-causing chemotherapy or monoclonal antibodies are given by ADCs. ADCs deliver cytotoxic drugs into the tumor cells, while BsAbs help the immune system recognize and attack cancer more efficiently. New and better antibody designs, linker technologies, and immunomodulation methods are currently being worked on to improve their safety and efficacy despite challenges posed by resistance, off-target toxicities, and manufacturing issues. On account of ever-growing clinical experience and vigorous research, these agents really have the potential to become the backbone around which personalized oncology is built. The easy integration of these agents into standard care and the strategic development of combinations and predictive biomarkers promises to vastly improve patient outcomes and change the entire industry of cancer treatment over the forthcoming years.

REFERENCES

1. Maeda H, Khatami M. Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs. Clin Transl Med, 2018 Mar 1; 7(1): 11
2. Min HY, Lee HY. Molecular targeted therapy for anticancer treatment. Exp Mol Med, 2022 Oct; 54(10): 1670-1694.
3. Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, De Falco V, Upadhyay A, Kandimalla R, Chaudhary A, Dhanjal JK, Dewanjee S, Vallamkondu J, Pérez de la Lastra JM. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis, 2022 Mar 18; 10(4): 1367-1401. doi: 10.1016/j.gendis.2022.02.007. Erratum in: Genes Dis, 2024 Jan 20; 11(4): 101211
4. Hong Y, Nam SM, Moon A. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry. Arch Pharm Res, 2023 Mar; 46(3): 131-148.
5. Laplagne C., Domagala M., le Naour A., et al. Latest advances in targeting the tumor microenvironment for tumor suppression. Int J Mol Sci, 2019; 20(19): 4719.
6. Naeem A, Hu P, Yang M, Zhang J, Liu Y, Zhu W, Zheng Q. Natural Products as Anticancer Agents: Current Status and Future Perspectives. Molecules, 2022; 27(23): 8367.
7. Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep, 2015 Jun 12; 35(4): e00225
8. Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduct Target Ther, 2022 Mar 22; 7(1): 93.

9. Quinteros DA, Bermúdez JM, Ravetti S, Cid A, Allemandi DA, Palma SD. Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery. Nanostructures for Drug Delivery, 2017: 807–33.
10. Riccardi F, Dal Bo M, Macor P, Toffoli G. A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy. Front Pharmacol, 2023 Sep 18; 14: 1274088.
11. Tashima T. Delivery of Drugs into Cancer Cells Using Antibody-Drug Conjugates Based on Receptor-Mediated Endocytosis and the Enhanced Permeability and Retention Effect. Antibodies (Basel), 2022 Dec 19; 11(4): 78
12. Hammood M, Craig AW, Leyton JV. Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development. Pharmaceuticals (Basel), 2021 Jul 15; 14(7): 674.
13. Mukhtar E, Adhami VM, Mukhtar H. Targeting microtubules by natural agents for cancer therapy. Mol Cancer Ther. 2014 Feb; 13(2): 275-84.
14. Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer, 2017 Dec 5; 117(12): 1736-1742
15. Chis AA, Dobrea CM, Arseniu AM, Frum A, Rus LL, Cormos G, Georgescu C, Morgovan C, Butuca A, Gligor FG, Vonica-Tincu AL. Antibody-Drug Conjugates-Evolution and Perspectives. Int J Mol Sci, 2024 Jun 26; 25(13): 6969.
16. Abelman RO, Wu B, Spring LM, Ellisen LW, Bardia A. Mechanisms of Resistance to Antibody-Drug Conjugates. Cancers (Basel), 2023 Feb 17; 15(4): 1278.
17. Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G. Acquired Resistance to Antibody-Drug Conjugates. Cancers (Basel), 2019 Mar 20; 11(3): 394.
18. Li S, Zhao X, Fu K, Zhu S, Pan C, Yang C, Wang F, To KKW, Fu L. Resistance to antibody-drug conjugates: A review. Acta Pharm Sin B, 2025 Feb; 15(2): 737-756.
19. Zhao P, Zhang Y, Li W, Jeanty C, Xiang G, Dong Y. Recent advances of antibody drug conjugates for clinical applications. Acta Pharm Sin B, 2020 Sep; 10(9): 1589-1600
20. Professional Committee on Clinical Research of Oncology Drugs, Chinese Anti-Cancer Association; Expert Committee for Monitoring the Clinical Application of Antitumor Drugs; Breast Cancer Expert Committee of National Cancer Quality Control Center; Cancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement Center. Expert consensus on the clinical application of antibody-drug conjugates in the treatment of malignant tumors (2021 edition). Cancer Innov, 2022 Jun 19; 1(1): 3-24.
21. Tsuchikama K., An Z. Antibody–drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell, 2018; 9: 33–46.
22. He J, Zeng X, Wang C, Wang E, Li Y. Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies. MedComm (2020), 2024 Jul 28; 5(8): e671.
23. Sun Y, Yu X, Wang X, Yuan K, Wang G, Hu L, Zhang G, Pei W, Wang L, Sun C, Yang P. Bispecific antibodies in cancer therapy: Target selection and regulatory requirements. Acta Pharm Sin B, 2023 Sep; 13(9): 3583-3597.
24. Ordóñez-Reyes C, Garcia-Robledo JE, Chamorro DF, Mosquera A, Sussmann L, Ruiz-Patiño A, Arrieta O, Zatarain-Barrón L, Rojas L, Russo A, de Miguel-Perez D, Rolfo C, Cardona AF. Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question. Pharmaceutics, 2022 Jun 11; 14(6): 1243.

25. Wang Q, Chen Y, Park J, Liu X, Hu Y, Wang T, McFarland K, Betenbaugh MJ. Design and Production of Bispecific Antibodies. Antibodies (Basel), 2019 Aug 2; 8(3): 43.
26. adsen AV, Pedersen LE, Kristensen P, Goletz S. Design and engineering of bispecific antibodies: insights and practical considerations. Front Bioeng Biotechnol, 2024 Jan 25; 12: 1352014.
27. Moon D, Tae N, Park Y, Lee SW, Kim DH. Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody. Immune Netw, 2022 Feb 14; 22(1): e4.
28. Huang S, van Duijnhoven SMJ, Sijts AJAM, van Elsas A. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy. J Cancer Res Clin Oncol, 2020 Dec; 146(12): 3111-3122.
29. Gu Y, Wang Z, Wang Y. Bispecific antibody drug conjugates: Making 1+1>2. Acta Pharm Sin B, 2024 May; 14(5): 1965-1986.
30. Zhang T, Lin Y, Gao Q. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy. Cancer Biol Med, 2023 Mar 24; 20(3): 181–95.
31. Moody PR, Sayers EJ, Magnusson JP, Alexander C, Borri P, Watson P, Jones AT. Receptor Crosslinking: A General Method to Trigger Internalization and Lysosomal Targeting of Therapeutic Receptor:Ligand Complexes. Mol Ther, 2015 Dec; 23(12): 1888-98
32. Li H, Er Saw P, Song E. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell Mol Immunol, 2020 May; 17(5): 451-461.
33. Wu, Y., Yi, M., Zhu, S. et al. Recent advances and challenges of bispecific antibodies in solid tumors. Exp Hematol Oncol, 2021; 10: 56.
34. Ma J, Mo Y, Tang M, Shen J, Qi Y, Zhao W, Huang Y, Xu Y, Qian C. Bispecific Antibodies: From Research to Clinical Application. Front Immunol, 2021 May 5; 12: 626616
35. Fan, G., Wang, Z., Hao, M. et al. Bispecific antibodies and their applications. J Hematol Oncol, 2015; 8: 130.
36. Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, White C, Lowe C, Sherba JJ, Hartmanshenn C, O'Neill KM, Balter ML, Fritz ZR, Androulakis IP, Schloss RS, Yarmush ML. The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci), 2018 Sep-Dec; 6(3-4): 79-100.
37. Shim H. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations. Biomolecules, 2020 Feb 26; 10(3): 360.
38. Barilà G, Rizzi R, Zambello R, Musto P. Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf. Pharmaceuticals (Basel), 2021 Jan 7; 14(1): 40.
39. Wei J, Yang Y, Wang G, Liu M. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol, 2022 Oct 28; 13: 1035276.
40. Wang, R., Hu, B., Pan, Z. et al. Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol, 2025; 18: 51.